I. MODIFIED AGREEMENTS

Company* (Country; Symbol)

Company* (Country; Symbol)

Change from original agreement

Terms/Details (Date)


Cambridge Antibody Technology Group plc (UK; CATG)

Amgen Inc. (AMGN)

Restructured deal under which Amgen takes over development responsibility for antibodies covered by the agreement

CAT is eligible to receive milestone and royalty payments; it also gets an up-front payment; the deal originally was signed with Immunex Corp., which was acquired by Amgen (12/24)

Cellular Genomics Inc.*

Serono SA (Switzerland)

Expansion of kinase discovery program to include a fifth kinase of interest to Serono

CGI is applying its chemical genetics technologies to drug targets selected by Serono under an October 2002 deal (11/18)

Genetronics Biomedical Corp. (AMEX:GEB)

Chiron Corp. (CHIR)

Extended collaboration to conduct additional experiments using Genetronics' electroporation technology

The experiments will be on a Chiron DNA HIV vaccine; terms were not disclosed (12/2)

Gen-Probe Inc. (GPRO)

Chiron Corp. (CHIR)

Amended worldwide blood screening collaboration to adopt a fixed revenue ratio

Gen-Probe will get 45.75% on revenues for assays that include a test for hepatitis C virus; the share remains 50% for other assays; the deal also precludes the naming of a third-party distributor in the U.S. (11/12)

Protein Design Labs Inc. (PDLI)

Genentech Inc. (NYSE:DNA)

Companies entered agreement settling dispute relating to humanized antibodies

Genentech exercised licenses for Xolair and Raptiva, and Avastin if approved, in exchange for license fees and royalties; PDL will get reduced royalty rates, and separately got nonexclusive rights to Genentech antibody patents (12/22)

Seattle Genetics Inc. (SGEN)

Protein Design Labs Inc. (PDLI)

PDL exercised an option for an exclusive license to an antigen target

The option came from a June 2001 collaboration in antibody-drug conjugates; Seattle Genetics got an undisclosed payment (12/23)

Seattle Genetics Inc. (SGEN)

Genentech Inc. (NYSE:DNA)

Expanded collaboration under which Genentech gets the right to use antibody-drug conjugate technology against additional targets

The deal expands their April 2002 pact; Seattle Genetics is getting a $3M payment and a $7M equity investment under terms of the expansion (12/19)

Tranzyme Inc.*

NeoGenesis Pharmaceuticals Inc.*

Expanded deal to include additional genes of interest

The August 2001 collaboration will continue, using Tranzyme's protein expression technology in support of chemical genomics program at NeoGenesis; terms were not disclosed (11/25)

II. TERMINATED AGREEMENTS

Enzo Life Sciences Inc. (subsidiary of Enzo Biochem Inc.; NYSE:ENZ)

Affymetrix Inc. (AFFX)

Enzo said it terminated the collaboration and filed a lawsuit against Affymetrix

Enzo alleged Affmetrix breached the agreement in various ways, including misappropriating Enzo assets (10/28)

Immunomedics Inc. (IMMU)

Amgen Inc. (AMGN)

Amgen said it would not begin a registration study of epratuzamab in non-Hodgkin's lymphoma and was seeking another party to take over its rights to the drug candidate

The move followed an unsuccesful attempt months earlier to negotiate an expanded license agreement that would have given Amgen global rights; the original deal was signed in December 2000; a monotherapy trial in NHL did not meet the standards Amgen was looking for (11/11)


Notes:

# The information in the chart does not cover agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange.